46
Participants
Start Date
January 31, 2015
Primary Completion Date
March 31, 2016
Study Completion Date
March 31, 2016
4 mg CLS-TA
40 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
Sham
suprachoroidal sham procedure
IVT aflibercept
2 mg intravitreal injection of aflibercept
Baltimore
Winston-Salem
Atlanta
Boynton Beach
Rapid City
St Louis
Houston
The Woodlands
San Antonio
McAllen
Abilene
Phoenix
Beverly Hills
San Diego
Lead Sponsor
Clearside Biomedical, Inc.
INDUSTRY